WaveLife Flat on Q2 Results
Shares in Wave Life Sciences Ltd. (NASDAQ: WVE) were unchanged Wednesday. The Cambridge, Mass.-based concern, a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the second quarter ended June 30, 2025. Wednesday morning’s news release reported cash and cash equivalents were $208.5 million as of June 30, 2025, compared to $302.1 million as of December 31, 2024. Wave expects that its current cash and cash equivalents will be sufficient to fund operations into 2027. Potential future milestones and other payments to Wave under its GSK collaboration are not included in its cash runway.Revenue recognized was $8.7 million for the second quarter of 2025 as compared to $19.7 million in the prior year quarter.Research and development expenses were $43.5 million in the second quarter of 2025 as compared to $40.4 million in the same period in 2024.General and administrative expenses were $18.0 million in the second quarter 2025 as compared to $14.3 million in the same period in 2024.Net loss was $50.5 million for the second quarter of 2025 as compared to $32.9 million in the prior year quarter.WVE shares gathered a penny to $8.33
Recent Posts

Europe Faces Most Difficult Moment in Bid to Avoid Split With US

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Hastings Racecourse in Vancouver to shut down permanently, operator says

Russia’s Vital Oil Trade With India Is Down, But Not Out

Copper Quest Closes $1,927,000 Private Placement

This TSX stock was up 17% this week and it could gain another 36%, analysts say

AMC Entertainment Holdings, Inc. Transfers the Majority of its Equity Investment in Hycroft Mining Holding Corporation to Sprott Mining for a Net Consideration of $24.1 million

Guardian Capital Announces Estimated 2025 Annual Non-Cash Distributions for Guardian Capital ETFs

Emera Renews At-The-Market Equity Program

CRA warns of ‘aggressive tax schemes’ involving critical illness insurance


